

# Appendix 4D

(Rule 4.2A.3)

## Half year report

Name of entity

Nanoveu Limited	97 624 421 085
-----------------	----------------

### 1. Details of the Reporting Period and the Previous Corresponding Period

Financial period ended ("current period")	Financial period ended ("previous period")
30 June 2020	30 June 2019

### 2. Results for Announcement to the Market

					\$'000
2.1	Revenue from ordinary activities	up	351%	to	18
2.2	Loss from ordinary activities after tax attributable to members	down	55%	to	836
2.3	Net loss for the period attributable to members	down	55%	to	836
2.4	Loss per share	down	55%	to	0.6 cents
2.5	<b>Brief explanation of results</b>				
	For further details, please refer to the interim financial report.				

### 3. NTA Backing

	Current period	Previous corresponding period
Net tangible asset backing per ordinary security	\$0.0094	\$0.0322

### 4. Control gained or lost over entities having material effect

Not applicable.

For personal use only

**5. Dividends**

There were no dividends declared or paid during the period and the do not recommend that any dividends be paid.

**6. Dividend Reinvestment Plans**

Not applicable.

**7. Material interest in entities which are not controlled entities**

Not applicable.

**8. Independent Review Report**

Refer to the attached Half Year Financial Report for the half-year ended 30 June 2020.

**9. Compliance Statement**

This report should be read in conjunction with the attached Half-year Financial Report for the half-year ended 30 June 2020.

Signed here:



Date: 27<sup>th</sup> August 2020

Print name: Alfred Chong  
Executive Chairman and CEO



## **Nanoveu Limited**

(ACN 624 421 085)

**INTERIM FINANCIAL REPORT  
FOR THE HALF-YEAR ENDED**

**30 June 2020**

For personal use only

For personal use only

<b>CONTENTS</b>	<b>PAGE</b>
Company Directory	1
Directors' Report	2
Auditor's Independence Declaration	4
Consolidated Statement of Profit or Loss and Other Comprehensive Income	5
Consolidated Statement of Financial Position	6
Consolidated Statement of Changes in Equity	7
Consolidated Statement of Cash Flows	8
Notes to the Consolidated Financial Statements	9 – 16
Directors' Declaration	17
Independent Auditor's Review Report	18

# COMPANY DIRECTORY

## Directors

Mr Alfred Chong  
Executive Chairman

Mr Michael van Uffelen  
Executive Director

Mr Steven Apedaile  
Non-executive Director

Mr David Nicol  
Non-executive Director

## Company Secretary

Mr Michael van Uffelen

## Share Registry

Automic Registry Services  
Level 2  
267 St Georges Terrace  
Perth WA 6000

Telephone (within Australia): 1300 288 664  
Telephone (outside Australia): +61 2 9698 5414

Email: [hello@automic.com.au](mailto:hello@automic.com.au)

## ABN:

97 624 421 085

## Registered Office

1/18 Olive Street  
Subiaco WA 6008

Tel: +61 8 6244 9095

## Web Address

[www.nanoveu.com](http://www.nanoveu.com)

## ASX Code:

NVU

## Auditors

BDO Audit (WA) Pty Ltd  
38 Station Street  
Subiaco WA 6008

## Solicitors

Steinepreis Paganin  
Level 4, The Read Buildings  
16 Milligan Street  
Perth WA 6000

## DIRECTORS' REPORT

Your Directors submit the financial report of the Company, being Nanoveu Limited, and the entities it controlled ("the Group"), for the half-year ended 30 June 2020. In order to comply with the provisions of the Corporations Act 2001, the Directors report as follows:

### Directors

The names of Directors who held office during or since the end of the half-year and until the date of this report are as below. Directors were in office for this entire period unless otherwise stated.

Alfred Chong	Executive Chairman and CEO
Michael van Uffelen	Executive Director, Company Secretary and CFO
Steven Apedaile	Independent Non-executive Director
David Nicol	Independent Non-executive Director

### Review of Operations

The loss for the half-year period for the Group after providing for income tax amounted to \$835,660 (2019: \$1,871,487).

Nanoveu's EyeFly3D™ product converts 2D digital displays into 3D without the need for 3D glasses. EyeFly3D™ has won numerous industry awards and is currently available for Apple iPhones and Google Pixel 3 phones.

Nanoveu is expanding its product range with the development of three complementary technologies:

- EyeFyx, to enable people with age-related farsightedness (presbyopia, one of the most common types of vision loss, affecting nearly one-quarter of the world's population and anyone living beyond middle age) to read smartphones and tablets without wearing reading glasses;
- Anti-reflective protectors, reducing screen reflection for smart phones and tablets; and
- Antiviral protectors, providing protection from viruses and bacteria.

Further, Nanoveu offers laminating machines for precise and bacterial free installation of its products on smart phones.

### Significant changes in the state of affairs

There were no significant changes in the state of affairs of the Group during the financial half-year.

### Events After the Balance Sheet Date

Subsequent to reporting date the Company secured a funding facility of up to \$2.4 million from Antiviral Technologies Portfolio LLC ("the Investor") for subscriptions for ordinary shares of the Company as follows:

- A \$600,000 subscription for shares with the value of \$658,500 has been received by the Company.
- A \$600,000 subscription for shares with the value of \$658,500 to be made subject to the Company obtaining shareholder approval for that subscription.
- An additional \$400,000 subscription for shares with the value of \$439,000 to be made (at the Investor's election) no later than at the first anniversary, subject to the Company obtaining shareholder approval for that subscription.

## DIRECTORS' REPORT

- An additional \$800,000 subscription for shares with the value of \$878,000 may be made by mutual consent of the parties, subject to the Company obtaining shareholder approval for that subscription.

Each of these investments will be made by way of the Investor prepaying for shares which will be issued upon the Investor's written request, within 18 months of the final subscription, in the number determined by applying to the subscription amount prepaid for by the Investor the "Purchase Price", being the average of the five daily volume-weighted average prices (rounded down to the next one tenth of a cent, or if the share price exceeds \$0.10, the next half a cent) selected by the Investor at its discretion during the 20 consecutive actual trading days immediately prior to the Investor's written request. Each issue must be for no less than \$150,000 of the shares.

The Company has made an initial issuance of 3,500,000 shares to the Investor; the remainder of shares will be issued as set out above. Alternatively, in lieu of applying these shares towards the aggregate number of the Placement Shares to be issued by Nanoveu, the Investor may, at a date determined by the Investor (no later than five business days after the later of the date of termination of the Agreement or the date by which all of the investments under the Agreement have been made, and all of the shares issuable under the Agreement have been issued), elect to make a further payment to the Company equal to the value of these shares determined using the Purchase Price at the time of the payment.

The Company has:

- paid a fee to the Investor of \$100,000 (equivalent to 4.2% of the maximum placement amount), satisfied by way of an issuance of 1,587,302 Shares to the Investor; and
- agreed, subject to shareholders' approval, to grant to the Investor 3,900,000 unlisted options to acquire ordinary shares at \$0.1018 each on or before 36-month anniversary of their grant date. This exercise price is at a 40% premium to the average of the daily VWAPs for Shares for the 20 consecutive actual trading days immediately prior to the date of the Agreement.

221,000 shares were issued after period end following the achievement of a performance hurdle.

The impact of the Coronavirus (COVID-19) pandemic is ongoing and it is not practicable to estimate the potential impact, positive or negative, after the reporting period. The situation is rapidly developing and is dependent on measures imposed by the Australian Government and other countries, such as maintaining social distancing requirements, quarantine, travel restrictions and any economic stimulus that may be provided.

Apart from the items above, no matters or circumstances have arisen since the end of the financial year which significantly affected or may significantly affect the operations of the Group, the results of those operations, or the state of affairs in future financial years.

### Auditor's Independence Declaration

Section 307C of the Corporations Act 2001 requires our auditors, BDO Audit (WA) Pty Ltd, to provide the Directors of the Company with an Independence Declaration in relation to the review of the half-year financial report. This Independence Declaration is set out on page 4 and forms part of this Directors' report for the half-year ended 30 June 2020.

This report is signed in accordance with a resolution of the Board of Directors made pursuant to section 306(3)(a) of the Corporations Act 2001.



Mr Alfred Chong  
Executive Chairman and CEO

Dated this 27<sup>th</sup> day of August 2020

## DECLARATION OF INDEPENDENCE BY PHILLIP MURDOCH TO THE DIRECTORS OF NANOVEU LIMITED

As lead auditor for the review of Nanoveu Limited for the half-year ended 30 June 2020, I declare that, to the best of my knowledge and belief, there have been:

1. No contraventions of the auditor independence requirements of the Corporations Act 2001 in relation to the review; and
2. No contraventions of any applicable code of professional conduct in relation to the review.

This declaration is in respect of Nanoveu Limited and the entities it controlled during the period.



Phillip Murdoch

Director

BDO Audit (WA) Pty Ltd

Perth, 27 August 2020



# CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

HALF-YEAR ENDED 30 JUNE 2020

	Note	Half-Year Ended 30/06/2020 \$	Half-Year Ended 30/06/2019 \$
Revenue from contracts with customers		17,514	3,884
<b>Revenue</b>		<b>17,514</b>	<b>3,884</b>
Cost of sale of goods		(12,656)	(3,594)
<b>Gross profit</b>		<b>4,858</b>	<b>290</b>
Other operating income		76,719	12,424
Selling and distribution expenses		(168,864)	(135,811)
Administration expenses		(518,723)	(910,613)
Research and development costs		(134,210)	(802,080)
Share based payment expense	7	(96,317)	(68,780)
<b>Operating loss</b>		<b>(836,537)</b>	<b>(1,904,570)</b>
Finance income		994	33,083
Finance costs		(117)	-
<b>Loss before income tax</b>		<b>(835,660)</b>	<b>(1,871,487)</b>
Income tax expense		-	-
<b>Loss for the year</b>		<b>(835,660)</b>	<b>(1,871,487)</b>
<b>Other comprehensive income / (loss)</b>			
<i>Items that may be reclassified to profit or loss:</i>			
- Currency translation differences arising from consolidation		4,790	12,359
		4,790	12,359
<b>Total comprehensive loss for the year</b>		<b>(830,870)</b>	<b>(1,859,128)</b>
Loss per share – basic and diluted	3	(0.6)	(1.4)

The above Consolidated Statement of Profit or Loss and Other Comprehensive Income should be read in conjunction with the accompanying notes

# CONSOLIDATED STATEMENT OF FINANCIAL POSITION

AS AT 30 JUNE 2020

	Note	30 June 2020 \$	31 December 2019 \$
<b>CURRENT ASSETS</b>			
Cash and cash equivalents		1,002,764	2,195,407
Other receivables		191,723	189,337
Inventories	5	245,590	-
Right of use asset		29,617	28,046
<b>Total Current Assets</b>		<b>1,469,694</b>	<b>2,412,790</b>
<b>NON-CURRENT ASSETS</b>			
Plant and equipment		102,095	126,149
Right of use asset		-	15,873
<b>Total Non-current Assets</b>		<b>102,095</b>	<b>142,022</b>
<b>TOTAL ASSETS</b>		<b>1,571,789</b>	<b>2,554,812</b>
<b>CURRENT LIABILITIES</b>			
Trade and other payables		295,113	529,281
Lease liability		29,617	28,046
<b>Total Current Liabilities</b>		<b>324,730</b>	<b>557,327</b>
<b>NON-CURRENT LIABILITIES</b>			
Lease liability		-	15,873
<b>Total Non-current Liabilities</b>		<b>-</b>	<b>15,873</b>
<b>TOTAL LIABILITIES</b>		<b>324,730</b>	<b>573,200</b>
<b>NET ASSETS</b>		<b>1,247,059</b>	<b>1,981,612</b>
<b>EQUITY</b>			
Issued capital	6	13,372,408	13,372,408
Accumulated losses		(11,022,375)	(10,186,715)
Reserves		(1,102,974)	(1,204,081)
<b>TOTAL EQUITY</b>		<b>1,247,059</b>	<b>1,981,612</b>

The above Consolidated Statement of Financial Position should be read in conjunction with the accompanying notes

# CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

HALF-YEAR ENDED 30 JUNE 2020

	Issued Capital	Accumulated Losses	Common Control Reserve	Share Based Payment Reserve	Foreign Currency Translation Reserve	Total
	\$	\$	\$	\$	\$	\$
Balance at 1 January 2019	13,372,408	(6,813,697)	(1,710,087)	263,040	72,423	5,184,087
Loss for the half-year	-	(1,871,487)	-	-	12,359	(1,859,128)
Total comprehensive loss for the year	-	(1,871,487)	-	-	12,359	(1,859,128)
<i>Transactions with owners in their capacity as owners:</i>						
Share based payments	-	-	-	68,780	-	68,780
<b>Balance at 30 June 2019</b>	<b>13,372,408</b>	<b>(8,685,184)</b>	<b>(1,710,087)</b>	<b>331,820</b>	<b>84,782</b>	<b>3,393,739</b>
Balance at 1 January 2020	13,372,408	(10,186,715)	(1,710,087)	424,875	81,131	1,981,612
Loss for the half-year	-	(835,660)	-	-	4,790	(830,870)
Total comprehensive loss for the year	-	(835,660)	-	-	4,790	(830,870)
<i>Transactions with owners in their capacity as owners:</i>						
Share based payments	-	-	-	96,317	-	96,317
<b>Balance at 30 June 2020</b>	<b>13,372,408</b>	<b>(11,022,375)</b>	<b>(1,710,087)</b>	<b>521,192</b>	<b>85,921</b>	<b>1,247,059</b>

The above Consolidated Statement of Statement of Changes in Equity should be read in conjunction with the accompanying notes

# CONSOLIDATED STATEMENT OF CASH FLOWS

HALF-YEAR ENDED 30 JUNE 2020

	Half-Year Ended 30/06/2020 \$	Half-Year Ended 30/06/2019 \$
<b>Cash flows from Operating Activities</b>		
Receipts from customers	17,514	3,884
Government grant received	76,719	12,313
Payments to suppliers and employees	(1,287,870)	(1,312,715)
Interest received	994	33,083
<b>Net cash (used in) operating activities</b>	<b>(1,192,643)</b>	<b>(1,263,436)</b>
<b>Cash Flows from Investing Activities</b>		
Purchase of plant and equipment	-	(118,290)
Term deposit redeemed	-	2,000,000
<b>Net cash provided by (used in) / investing activities</b>	<b>-</b>	<b>1,881,710</b>
Net increase (decrease) in cash held	(1,192,643)	618,274
Cash at the beginning of the financial period	2,195,407	2,908,108
<b>Cash at the end of the financial period</b>	<b>1,002,764</b>	<b>3,526,382</b>

The above Consolidated Statement of Cash Flows should be read in conjunction with the accompanying notes

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

## 1. SIGNIFICANT ACCOUNTING POLICIES

### Basis of Preparation

These general purpose financial statements for the interim half-year reporting period ended 30 June 2020 have been prepared in accordance with Australian Accounting Standard AASB 134 'Interim Financial Reporting' and the Corporations Act 2001, as appropriate for for-profit oriented entities. Compliance with AASB 134 ensures compliance with International Financial Reporting Standard IAS 34 'Interim Financial Reporting'.

It is recommended that the financial statements are read in conjunction with the annual financial report for the year ended 31 December 2019 and any public announcements made by the Company during the half-year in accordance with continuous disclosure requirements arising under the Corporations Act 2001 and the ASX Listing Rules.

The interim financial statements have been approved and authorised for issue by the Board on 27 August 2020.

The principal accounting policies adopted are consistent with those of the previous financial year and corresponding interim reporting period, unless otherwise stated.

### Going concern

The interim financial report has been prepared on a going concern basis, which contemplates the continuity of normal business activity and the realisation of assets and the settlement of liabilities in the ordinary course of business. The Group incurred a loss for the half year ended 30 June 2020 of \$835,660 (2019: \$1,871,487) and net cash outflows from operating activities of \$1,192,643 (2019: \$1,263,436).

The ability of the Group to continue as a going concern is dependent on securing additional funding through either equity, debt or receipts, or a combination of all, to continue to fund its operational and technology development activities. These conditions indicate a material uncertainty that may cast a significant doubt about the Group's ability to continue as a going concern and, therefore, that it may be unable to realise its assets and discharge its liabilities in the normal course of business.

The Directors believe that there are sufficient funds available to continue to meet the Group's working capital requirements as at the date of this report and that sufficient funds will be available to finance the operations of the Group for the following reasons:

- The Directors of Nanoveu Limited have assessed the likely cash flow for the 12 month period from date of signing this half year report and its impact on the Group and believe there will be sufficient funds to meet the Group's working capital requirements as at the date of this report, based on the belief that additional funds will be receipted via product sales to finance the Company's activity and from a funding facility of up to \$2.4 million secured subsequent to period end (see Note 10).
- The Group has historically demonstrated its ability to raise funds to satisfy its immediate cash requirements. Management have considered the future capital requirements of the Group and will consider all funding options as required.
- The Directors of Nanoveu Limited have reason to believe that in addition to the cash flow currently available, additional funds from receipts are expected from the commercialisation of the Group's products.

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

## 1. SIGNIFICANT ACCOUNTING POLICIES (continued)

Should the Group not be able to continue as a going concern, it may be required to realise its assets and discharge its liabilities other than in the ordinary course of business, and at amounts that differ from those stated in the financial statements or raise additional capital through equity or debts raisings and that the interim financial report does not include any adjustments relating to the recoverability and classification of recorded asset amounts or liabilities that might be necessary should the Group not continue as a going concern and meet its debts as and when they become due and payable.

### **Basis of Measurement and Reporting Conventions**

The financial statements, except for cash flow information, have been prepared on an accruals basis and are based on historical costs, modified, where applicable, by the measurement at fair value of selected non-current assets, financial assets and financial liabilities. The amounts presented in the financial statements have been rounded off to the nearest dollar unless stated otherwise.

The accounting policies adopted are consistent with the accounting policies adopted in the Group's last annual financial statements for the year ended 31 December 2019 except for the adoption of new and amended standards adopted by the Group. Comparative figures have been adjusted to conform to changes in presentation for the current financial year.

### **New, revised or amending Accounting Standards and Interpretations adopted**

The Group has adopted all of the new, revised or amending Accounting Standards and Interpretations issued by the Australian Accounting Standards Board that are mandatory for the current reporting period. The adoption of these Accounting Standards and Interpretations did not have any significant or material change to the Group's accounting policies.

Any new, revised or amending Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.

### **Functional and presentation currency**

These financial statements are presented in Australian dollars, which is the functional currency of Nanoveu Limited.

### **Critical estimates and judgements**

#### *Performance rights*

4,980,000 performance rights are on issue which convert into fully paid ordinary shares on the achievement of the milestones as disclosed in Note 7. If the milestone is not satisfied on or before expected achievement dates, the Performance Rights will expire.

For remuneration and expense recognition purposes the value is the number of performance rights granted, multiplied by the share price at date of grant and the value being amortised over the period to the expected vesting date after assessing the likelihood, probability and date of achieving these milestones. These are then reassessed at each reporting date for performance rights which have not been achieved nor expired.

#### *Performance Options*

The Group measures the cost of equity-settled share-based payments at fair value at the grant date using an option pricing model, taking into account the terms and conditions upon which the instruments were granted. The fair value is determined by a valuation using a Black Scholes Option Pricing Model.

The probability of achieving non-market based performance milestones is assessed at each reporting date. As at 30 June 2020, no expense has been recognised in respect of the performance options issued to the consultants as a 0% probability has been assigned to meeting the respective milestones.

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

## 1. SIGNIFICANT ACCOUNTING POLICIES (continued)

### Coronavirus (COVID-19) pandemic

On 31 January 2020, the World Health Organisation (WHO) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (COVID-19 outbreak) and the risks to the international community as the virus spreads globally beyond its point of origin. Because of the rapid increase in exposure globally, on 11 March 2020, the WHO classified the COVID-19 outbreak as a pandemic.

The full impact of the COVID-19 outbreak continues to evolve at the date of this report. The Group is therefore uncertain as to the full impact that the pandemic will have on its financial condition, liquidity, and future results of operations during 2020 and 2021. Management is actively monitoring the global situation and its impact on the Group's financial condition, liquidity, operations, suppliers, industry, and workforce. Given the daily evolution of the COVID-19 outbreak and the global responses to curb its spread, the Group is not able to estimate the effects of the COVID-19 outbreak on its results of operations, financial condition, or liquidity for the 2020 financial year.

Although the company cannot estimate the length or gravity of the impact of the COVID-19 outbreak at this time, if the pandemic continues, it may have a material adverse effect on the Group's results of future operations, financial position, and liquidity in the fiscal year 2020 and 2021.

## 2. SEGMENT REPORTING

The Group predominantly deploys nanotechnology in vision applications for consumer devices industry. For management purposes, the Group is organised into business units based on its services and has three reportable segments, as follows:

- Americas;
- rest of the world; and
- corporate and head office.

No operating segments have been aggregated to form the above reportable operating segments.

Management monitors the operating results of its business units separately for the purpose of making decisions about resource allocation and performance assessment. Segment performance is evaluated based on profit or loss and is measured consistently with profit or loss in the consolidated financial statements. The Group's financing (including finance costs and finance income) and income taxes are managed on a Group basis and are not allocated to operating segments.

Transfer prices between operating segments are on an arm's length basis in a manner similar to transactions with third parties.

Half-year Ended 30 June 2020	Americas	Rest of the World	Corporate and Head Office	Total Segments	Adjustments and Eliminations	Consolidated
<b>Revenue</b>						
External customers	15,564	1,950	-	17,514	-	17,514
Inter-segment		-		-	-	-
Total revenue (i)	15,564	1,950	-	17,514	-	17,514
<b>Income/(expenses)</b>						
Depreciation and amortisation	-	(23,513)	-	(23,513)	-	(23,513)
Segment profit/(loss)	(44,974)	(292,655)	(498,030)	(835,660)	-	(835,660)
Total assets	3,028	613,167	955,594	1,571,789	-	1,571,789
Total liabilities	(4,219)	(266,325)	(54,187)	(324,730)	-	(324,730)

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

## 2. SEGMENT REPORTING (continued)

Half-year Ended 30 June 2019	Americas	Rest of the World	Corporate and Head Office	Total Segments	Adjustments and Eliminations	Consolidated
<b>Revenue</b>						
External customers	162	3,722	-	3,884	-	3,884
Inter-segment		-		-	-	-
Total revenue (i)	162	3,722	-	3,884	-	3,884
<b>Income/(expenses)</b>						
Depreciation and amortisation	-	(42,528)	-	(42,528)	-	(42,528)
Segment profit/(loss)	(86,729)	(1,341,472)	(443,286)	(835,660)	-	(835,660)
Total assets	15,494	1,072,486	3,314,795	4,402,775	(2)	4,402,773
Total liabilities	-	(988,339)	(20,695)	(1,009,034)	-	(1,009,034)

### Adjustments and eliminations

Finance income and costs, and fair value gains and losses on financial assets are not allocated to individual segments as the underlying instruments are managed on a group basis. Current taxes and certain financial assets and liabilities are not allocated to those segments as they are also managed on a group basis. Inter-segment revenues are eliminated on consolidation.

- (i) Revenue is recognised at a point in time.

## 3. LOSS PER SHARE

	Half-year Ended 30/06/2020	Half-year Ended 30/06/2019
(Loss) for the period	(\$835,660)	(\$1,871,487)
Weighted average number of ordinary shares used in the (loss) per share calculations	132,530,203	132,530,203
Basic and diluted (loss) per share (cents)	(0.6)	(1.4)

## 4. DIVIDENDS PAID OR PROPOSED

No dividends were paid or declared during the half-year ended 30 June 2020 (30 June 2019: nil).

## 5. INVENTORIES

	As at 30/06/2020	As at 31/12/2019
Work-in-progress	245,590	-
	245,590	-

Work-in-progress comprises of raw materials being processed into finished goods.



# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

## 6. ISSUED CAPITAL

### (a) Ordinary shares

	As at 30/06/2020	As at 31/12/2019
Paid up capital – ordinary shares	14,196,629	14,196,629
Capital raising costs	(824,221)	(824,221)
	<u>13,372,408</u>	<u>13,372,408</u>
	<b>Number of shares</b>	<b>\$</b>
<b>30 June 2020 movements in issued capital:</b>		
Balance at 1 January 2020	132,530,203	13,372,408
Movements	-	-
Balance at 30 June 2020	<u>132,530,203</u>	<u>13,372,408</u>

### (b) Performance Rights

During the period 4,980,000 Performance Rights were on issue. Refer to Note 7 for further information.

### (c) Options

No options were issued, exercised or lapsed during the period, apart from performance options issued as detailed in Note 7.

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

## 7. SHARE-BASED PAYMENTS

### (a) Performance Rights

During the period 4,980,000 Performance Rights were on issue.

The vesting of the Performance Rights is subject to the achievement of the following milestones:

Tranche	Performance Hurdle	Number	Assumed Probability of achievement	Assumed Achievement Date
A	Admission to the Official List of the Australian Securities Exchange Ltd and completion of 2 year of service	1,100,000	100%	30 November 2020
B	First sales of EyeFyx products achieved by 31 March 2021	850,000	100%	31 March 2021
C	Completion of iPhone Series X production of at least 100,000 units	455,000	100%	31 December 2020
D	Completion of production of the first three Android models of at least 100,000 units	443,000	100%	31 December 2020
E	Completion of gaming software development kit or launch of first five 3D games introduced to market	442,000	100%	30 June 2020
F	Securing distribution in China with sales of at least 100,000 units	620,000	100%	30 June 2021
H	\$5m of sales revenue across all products by 31 December 2020 as validated from audited / reviewed financial reports	1,070,000	100%	31 December 2020
<b>Total</b>		<b>4,980,000</b>		

50% of tranches B to H vest 12 months after the achievement of the respective performance hurdle, provided the employee remains in employment.

Any unvested Performance Rights will lapse 7 years after their date of issue.

The Tranche E performance hurdle was achieved during the period and 221,000 shares were issued after period end.

Tranches G and I previously expired.

### (b) Valuation of Performance Rights

Performance Rights are valued at the last price at which a share in the Company traded on the Australian Securities Exchange.

The fair value of Performance Rights is recognised as an expense over the period from grant to vesting date assuming the performance hurdle has been achieved.

The amount recognised as part of employee benefits expense for Performance Rights during the period was \$96,317 (2019: \$68,780), inclusive of all performance rights existing at the beginning of the half-year period and those issued during the half-year period.

### (c) Performance Options

During the period an agreement was signed with Digital 360 Consulting (D360), a leading agency specialising in product launches for disruptive technologies, for retail and go-to-market services in the USA, Canada and the UK for its antiviral smartphone screen and case protection products.

D360's remuneration includes 3,250,000 performance options which have an exercise price of \$0.20, expiry date of 31 December 2023 and are exercisable upon the following vesting conditions being achieved:

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

## 7. SHARE-BASED PAYMENTS (continued)

- (i) (Tranche 1): 500,000 Options shall vest upon Nanoveu generating US\$2,500,000 in revenue from sales of Nanoveu's antiviral protectors for smart phones to customers introduced to Nanoveu by D360 by the later of:
- (A) 31 December 2020; and
  - (B) the date which is 7 months from the date on which Nanoveu announces that Products are available for commercial sale;
- (ii) (Tranche 2): 750,000 Options shall vest upon Nanoveu generating US\$5,000,000 in revenue from sales of Nanoveu's antiviral protectors for smart phones to customers introduced to Nanoveu by D360 by the later of:
- (A) 31 December 2020; and
  - (B) the date which is 7 months from the date on which Nanoveu announces that Products are available for commercial sale;
- (iii) (Tranche 3): 1,000,000 Options shall vest upon Nanoveu generating US\$20,000,000 in revenue from sales of antiviral protectors for smart phones to customers introduced to Nanoveu by D360 by the later of:
- (A) 31 December 2021; and
  - (B) the date which is 19 months from the date on which Nanoveu announces that Products are available for commercial sale; and
- (iv) (Tranche 4): 1,000,000 Options shall vest upon Nanoveu generating US\$50,000,000 in revenue from sales of antiviral protectors for smart phones to customers introduced to Nanoveu by D360 by the later of:
- (A) 31 December 2022; or
  - (B) the date which is 31 months from date on which Nanoveu announces that Products are available for commercial sale.

### (d) Valuation of Performance Options

The fair value of performance options will be recognised as an expense if a performance hurdle is achieved.

No share-based payment expense was recognised in relation to the options issued during the half-year ended 30 June 2020. Option share-based payment expense will be recognised at the point the service is delivered, being on date the consultant engaged achieves the revenue targets set.

## 8. RELATED PARTY TRANSACTIONS

There were no other transactions with related parties during the half-year other than those that were on the same basis as stated in the 31 December 2019 Annual Report.

## 9. COMMITMENTS AND CONTINGENCIES

There has been no change in commitments or contingent liabilities since the last annual reporting date.

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

## 10. EVENTS AFTER THE BALANCE SHEET DATE

Subsequent to reporting date the Company secured a funding facility of up to \$2.4 million from Antiviral Technologies Portfolio LLC (“the Investor”) for subscriptions for ordinary shares of the Company as follows:

- A \$600,000 subscription for shares with the value of \$658,500 has been received by the Company.
- A \$600,000 subscription for shares with the value of \$658,500 to be made subject to the Company obtaining shareholder approval for that subscription.
- An additional \$400,000 subscription for shares with the value of \$439,000 to be made (at the Investor’s election) no later than at the first anniversary, subject to the Company obtaining shareholder approval for that subscription.
- An additional \$800,000 subscription for shares with the value of \$878,000 may be made by mutual consent of the parties, subject to the Company obtaining shareholder approval for that subscription.

Each of these investments will be made by way of the Investor prepaying for shares which will be issued upon the Investor’s written request, within 18 months of the final subscription, in the number determined by applying to the subscription amount prepaid for by the Investor the “Purchase Price”, being the average of the five daily volume-weighted average prices (rounded down to the next one tenth of a cent, or if the share price exceeds \$0.10, the next half a cent) selected by the Investor at its discretion during the 20 consecutive actual trading days immediately prior to the Investor’s written request. Each issue must be for no less than \$150,000 of the shares.

The Company has made an initial issuance of 3,500,000 shares to the Investor; the remainder of shares will be issued as set out above. Alternatively, in lieu of applying these shares towards the aggregate number of the Placement Shares to be issued by Nanoveu, the Investor may, at a date determined by the Investor (no later than five business days after the later of the date of termination of the Agreement or the date by which all of the investments under the Agreement have been made, and all of the shares issuable under the Agreement have been issued), elect to make a further payment to the Company equal to the value of these shares determined using the Purchase Price at the time of the payment.

The Company has:

- paid a fee to the Investor of \$100,000 (equivalent to 4.2% of the maximum placement amount), satisfied by way of an issuance of 1,587,302 Shares to the Investor; and
- agreed, subject to shareholders’ approval, to grant to the Investor 3,900,000 unlisted options to acquire ordinary shares at \$0.1018 each on or before 36-month anniversary of their grant date. This exercise price is at a 40% premium to the average of the daily VWAPs for Shares for the 20 consecutive actual trading days immediately prior to the date of the Agreement.

221,000 shares were issued after period end following the achievement of a performance hurdle.

The impact of the Coronavirus (COVID-19) pandemic is ongoing and it is not practicable to estimate the potential impact, positive or negative, after the reporting period. The situation is rapidly developing and is dependent on measures imposed by the Australian Government and other countries, such as maintaining social distancing requirements, quarantine, travel restrictions and any economic stimulus that may be provided.

Apart from the items above, no matters or circumstances have arisen since the end of the financial year which significantly affected or may significantly affect the operations of the Group, the results of those operations, or the state of affairs in future financial years.

# DIRECTORS' DECLARATION

In the directors' opinion:

- the attached financial statements and notes comply with the Corporations Act 2001, Australian Accounting Standard AASB 134 'Interim Financial Reporting', the Corporations Regulations 2001 and other mandatory professional reporting requirements;
- the attached financial statements and notes give a true and fair view of the Group's financial position as at 30 June 2020 and of its performance for the financial half-year ended on that date; and
- there are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable.

Signed in accordance with a resolution of directors made pursuant to section 303(5)(a) of the Corporations Act 2001.

On behalf of the directors



**Mr Alfred Chong**  
Executive Chairman and CEO  
27<sup>th</sup> August 2020

For personal use only

## INDEPENDENT AUDITOR'S REVIEW REPORT

To the members of Nanoveu Limited

### Report on the Half-Year Financial Report

#### Conclusion

We have reviewed the half-year financial report of Nanoveu Limited (the Company) and its subsidiaries (the Group), which comprises the consolidated statement of financial position as at 30 June 2020, the consolidated statement of profit or loss and other comprehensive income, the consolidated statement of changes in equity and the consolidated statement of cash flows for the half-year ended on that date, a summary of significant accounting policies and other explanatory information, and the directors' declaration.

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the accompanying half-year financial report of the Group does not comply with the Corporations Act 2001 including:

- (i) Giving a true and fair view of the Group's financial position as at 30 June 2020 and of its financial performance for the half-year ended on that date; and
- (ii) Complying with Accounting Standard AASB 134 Interim Financial Reporting and the Corporations Regulations 2001.

#### Basis for conclusion

We conducted our review in accordance with ASRE 2410 Review of a Financial Report Performed by the Independent Auditor of the Entity. Our responsibilities are further described in the Auditor's Responsibilities for the Review of the Financial Report section of our report. We are independent of the Company in accordance with the auditor independence requirements of the Corporations Act 2001 and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 Code of Ethics for Professional Accountants (including Independence Standards) (the Code) that are relevant to the audit of the annual financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We confirm that the independence declaration required by the Corporations Act 2001 which has been given to the directors of the Company, would be the same terms if given to the directors as at the time of this auditor's review report.

#### Material uncertainty relating to going concern

We draw attention to Note 1 in the financial report which describes the events and/or conditions which give rise to the existence of a material uncertainty that may cast significant doubt about the Group's ability to continue as a going concern and therefore the Group may be unable to realise its assets and discharge its liabilities in the normal course of business. Our conclusion is not modified in respect of this matter.

For personal use only



#### Responsibility of the directors for the financial report

The directors of the company are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the Corporations Act 2001 and for such internal control as the directors determine is necessary to enable the preparation of the half-year financial report that is free from material misstatement, whether due to fraud or error.

#### Auditor's responsibility for the review of the financial report

Our responsibility is to express a conclusion on the half-year financial report based on our review. ASRE 2410 requires us to conclude whether we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the Corporations Act 2001 including giving a true and fair view of the Company's financial position as at 30 June 2020 and its performance for the half-year ended on that date, and complying with Accounting Standard AASB 134 Interim Financial Reporting and the Corporations Regulations 2001.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

BDO Audit (WA) Pty Ltd

BDO  
A handwritten signature in black ink, appearing to read 'P. Murdoch', is written over a horizontal line.

Phillip Murdoch

Director

Perth, 27 August 2020